KAJALAKSHMY M. Phase Ii Trial Of Bevacizumab, Irinotecan, And Cetuximab In Recurrent Glioblastoma Multiforme: Efficacy, Safety And Clinical Outcomes. Journal for ReAttach Therapy and Developmental Diversities, [S. l.], v. 5, n. 2, p. 788–792, 2022. DOI: 10.53555/jrtdd.v5i2.3854. Disponível em: https://mail.jrtdd.com/index.php/journal/article/view/3854. Acesso em: 11 apr. 2026.